Original Contributions |
From the Division of Cardiology, Department of Veterans Affairs Hospital and Vanderbilt University Medical Center, Nashville, Tenn.
Correspondence to Paul R. Myers, PhD, MD, Division of Cardiology, MRB II, Room 358, Vanderbilt University Medical Center, 23rd Ave S and Pierce St, Nashville, TN 37202-6300.
| Abstract |
|---|
|
|
|---|
-nitro-L-arginine methyl
ester. Collagen type I and type III were quantitatively measured using
an enzyme-linked immunosorbent assay method. The
endothelium elicited a time-dependent increase in the
concentration of soluble VSMC-derived collagen type I; in contrast,
collagen type III was decreased. After inhibition of nitric oxide
production, there was a marked increase in both collagen types
I and III concentration. These results demonstrated that
endothelium-derived nitric oxide differentially alters
collagen subtypes produced by VSMCs. The data support the hypothesis
that nitric oxide functions via a paracrine mechanism to decrease VSMC
collagen types I and III concentration, a finding consistent
with an integral role for the endothelium in modulating
extracellular matrix metabolism.
Key Words: extracellular matrix nitric oxide collagen endothelium
| Introduction |
|---|
|
|
|---|
The vascular wall extracellular matrix comprises the bulk of the interstitium of the media and is composed of a complex mixture of extracellular matrix proteins, including collagens.18 The fibrillar collagens are the most abundant collagens, with subtypes I, III, and IV being most common.18 19 Atherogenesis and restenosis are two disease processes relevant to coronary artery vascular biology that are directly related to extracellular matrix collagen synthesis and degradation, primarily because the hallmark of the disease is mechanical obstruction of coronary blood flow secondary to medial and intimal hyperplasia. The importance of a functionally intact endothelium in atherosclerosis is firmly established.20 Less well characterized, however, is the role of the endothelium in extracellular matrix metabolism, despite the observation that the extracellular matrix comprises the bulk of the media in health and the bulk of the abnormal neointima during disease.
The purpose of the present study was to employ coronary endothelium and coronary VSMCs in a coculture configuration to more closely mimic a paracrine environment to test the hypothesis that endogenously derived endothelial cell NO directly affects collagen subtype concentrations. Prior research has demonstrated that NO donors alter collagen metabolism when added directly to VSMCs21 22 ; however, less is known with regard to the role of endogenously derived NO in vascular wall extracellular matrix metabolism. Since previous work has established that NO is produced by an endothelial constitutive enzyme, the experimental design employed a NOS antagonist to block endogenous synthesis of NO.
| Methods |
|---|
|
|
|---|
To obtain porcine VSMCs, the intima and adventitia were stripped off a
freshly harvested coronary artery and the media was cut into
1-mm2 pieces. Each piece of tissue was plated
directly into a 3.8-cm2 well of a 12-well plate
filled with 2 mL of filtered conditioned medium (medium 199 containing
Earle's salts and 0.1451 g neomycin) supplemented with 20% (vol/vol)
FBS (Hyclone). The dishes were placed into a 95% air/5%
CO2atmosphere incubator at 37°C and allowed
to grow until established colonies became apparent. Colonies of cells
were lightly trypsinized from the wells, and single cells were
transferred into 60-mm dishes with 5 mL of conditioned media and 10%
FBS. The resulting monocultures were subcultured and referred to as
first-passage cells. Cultured cells were confirmed as smooth muscle
cells by standard morphological criteria and immunohistochemical
staining with antibodies to the smooth musclespecific
-actin. The
failure to stain for factor VIII antigen was used as a negative
control.
Coculture Protocol
Endothelium
Identical numbers of cells (density of 1 to
3x105 cells per insert) were plated onto Falcon
inserts (catalog No. 3091, polystyrene, pore size 3 µ) in medium 199
with Earle's salts and 15% FBS. Inserts were allowed to incubate
under the same conditions (95% air/5% CO2) for
24 to 48 hours. The endothelial cells were washed with
warm PBS x2, then placed in 0.4% FBS for 24 hours. The wash routine
was repeated, at which time the medium was replaced with medium 199
with Earle's salts containing 0.4% FBS.
Vascular Smooth Muscle
Identical numbers of cells were plated onto Falcon six-well
dishes that served as "companion plates" (catalog No. 3502; density
of 1 to 3x105 cell per well) to the inserts on
which endothelium was grown. Cells were grown in medium
199 with Earle's salts and 15% FBS, allowed to incubate under the
same conditions 24 to 48 hours, then washed with warm PBS x2, and
placed into 2 mL medium supplemented with 0.4% FBS for another 24
hours.
Coculture
On the day of an experiment, growth medium was removed from the
wells containing VSMCs and also the inserts containing
endothelium. The insert was carefully lowered into the
companion well and medium (supplemented with 0.4% FBS) was then added
to the assembly, ensuring the absence of air bubbles. Drugs (50
µmol/L L-NAME and 5 µmol/L indomethacin, Sigma
Chemical Company) were added to the insert, and carrier was added to
the inserts of control wells. All experimental conditions were prepared
in triplicate.
Collagen Type I and III Assay
An ELISA, originally described by
Engvall,23 was modified and used to directly
measure soluble collagen in the growth medium. Soluble collagen was
assayed because previous studies demonstrated fibrillar collagen
synthesized in cell culture is soluble24 and
distributed primarily in the growth medium.25
Serial dilutions of antigen (human collagen, type I and type III;
Southern Biotechnology Associates) were prepared with SBB, pH 9.6. One
hundred microliters of each dilution was added to a well of a 96-well
modified flat-bottom polystyrene microtiter plate (Corning, model 25805
to 96) for generating a standard calibration curve. One hundred
microliters of the SBB was used to determine background. One
hundredmicroliter samples of growth medium with the amount of
collagen to be determined were added to separate wells on the same
plate. One hundred microliters of medium 199 supplemented with 0.4%
FBS incubated in blank companion wells containing an insert with no
cells served as control. The 96-well plate was incubated at 4°C for
24 hours in a humidified atmosphere. Excess antigen was removed by
washing three times with 100 mmol/L BBS, pH 8.0, with 0.05% Tween
20 (BBS-T, pH 8.0) in an automated microplate washer. Nonspecific
protein binding sites were blocked by completely filling the wells with
300 µL of 0.1% bovine serum albumin (pH 8.0) in BBS and
incubating at room temperature (25°C) with gentle shaking for 60
minutes. Excess albumin was removed by washing three times with
BBS-T. One hundred microliters of appropriate dilutions of primary
antibody against collagen type I (goat anti-human and bovine type 1
collagen; <10% cross-reactivity with collagen types II, III, IV, V,
and VI; Southern Biotechnology Associates) or against collagen type III
(goat antitype III collagen affinity purified antibody; <10%
cross-reactivity with types I, II, IV, and VI; Southern Biotechnology
Associates) was added to each well and incubated for 60 minutes at room
temperature with gentle shaking. Excess primary antibody was removed by
washing five times with BBS-T. One hundred microliters of appropriate
dilutions of biotin-conjugated secondary antibody (goat anti-rabbit IgG
H&L biotin-conjugated antibody, BioDesign International; or rabbit
anti-goat IgG H&L biotin-labeled antibody, Southern Biotechnology
Associates) was added to each well and incubated at room temperature
for 60 minutes with gentle shaking. Excess antibody was removed by
washing five times with BBS-T. One hundred microliters of a 1:8000
dilution of streptavidin horseradish peroxidaselabeled (Southern
Biotechnology Associates) solution was added to each well and incubated
for 60 minutes at room temperature with gentle shaking. Excess
streptavidin was removed by washing five times with BBS-T. One hundred
microliters of freshly prepared substrate for horseradish peroxidase
(ABTS, Sigma) was added to each well. Reaction products were
quantified by reading of the microplates at 405 nm in a microplate
autoreader spectrophotometer after 30 minutes. The optical density
reading of control standards (100 µL of SBB) was subtracted from
optical density readings of each test standard and hence calibration
curves for the determination of collagen types I and III by ELISA were
obtained. Optical density reading of control from culture media (100
µL of medium 199/0.4% FBS) was subtracted from optical density
readings from each unknown. The concentration of collagen type I and
collagen type III in the unknown was determined by using the linear
portion of the standard curve. The standards, appropriate controls, and
each unknown were prepared in duplicate and the values averaged.
Determination of ELISA Conditions for Collagen Type I and Type
III
For collagen type I, microtiter plates were coated
with serial dilutions of standard collagen type I (5000 to 11.5 ng/mL)
and incubated with serial dilutions of primary antibody (goat
anti-human type I, 1:1600) and secondary antibody (rabbit anti-goat IgG
H&L biotin-conjugated, 1:50 000). Streptavidin horseradish peroxidase
and ABTS incubations were done as described above to determine the
optimal primary and secondary antibody dilutions to yield linearity and
a good color reaction for the appropriate concentration range of
collagen type I.
For collagen type III, microtiter plates were coated with serial dilutions of standard collagen (2500 to 1.0 ng/mL) and incubated with serial dilutions of primary antibody (goat anti-human type III collagen affinity purified antibody, 1:100) and secondary antibody (rabbit anti-goat IgG H&L biotin-labeled, 1:10 000). Streptavidin horseradish peroxidase and ABTS incubations were done as described above to determine the optimal primary and secondary antibody dilutions to yield linearity and a good color reaction for the concentration range of collagen type III.
Determination of Protein Synthesis and Cell Counts
Cellular protein derived from both coronary artery VSMCs
and endothelium was determined according to
Bradford26 (BioRad) with bovine serum
albumin as a standard. Cell protein was solubilized with 0.1N
NaOH. Cells were manually counted in triplicate using a hemocytometer
and the manufacturer's instructions.
Experimental Protocol
Cocultures were performed according to the paradigm outlined in
the diagram below for 6, 12, 24, 36, or 48 hours' duration to
determine the optimal time period to elicit coculture effects on
collagen I and collagen III concentration in the growth medium. Since
maximal effects were seen at 24 to 36 hours, antagonist
studies were carried out at 36 hours' coculture.
L-NAME and/or indomethacin (to eliminate any potential confounding effects of cyclooxygenase products) were added to the coculture assembly and the medium and cells were harvested separately at the end of 36 hours. Cellular protein was determined on each sample and was taken to reflect the effects of coculture on cell division.
Data Analysis
The effects of coculture on either collagen I or collagen III
concentration was determined by A divided by B (see diagram).
Time-course data were obtained as nanograms collagen type I or type III
per microgram protein and expressed as the percent change relative to
VSMC cultures without endothelium. For any one number
(n), the average was calculated from measurements obtained from
triplicate cultures. Separate experiments on different days comprised a
sample number.
|
The effects of NOS inhibition (L-NAME) were expressed as both raw data (nanograms per microgram protein) and the mean of the percent change in collagen concentration elicited by the drug relative to cocultures without drug ±SEM (see diagram): [(C-A)/A] for coculture and [(D-B)/B] to ascertain the direct effects of drug on VSMCs alone.
The effects of coculture on VSMC cell protein (harvested from the well) were expressed as percentage determined as VSMC protein in the presence of endothelium divided by VSMCs in the absence of endothelium.
The effects of coculture on endothelial cell protein (harvested from the insert) were determined similarly.
Statistical significance between the amounts of collagen at different time points or the significance of the effects of NOS inhibition in coculture versus VSMCs alone was established using the two-tailed, unpaired Student's t test. P<.05 was considered statistically significant. Samples were always done in triplicate and n represents independent experiments done on separate dates. When multiple drug conditions were analyzed for statistical difference, data were compared by analysis of variance with a Bonferroni correction for multiple comparisons.
| Results |
|---|
|
|
|---|
Separate experiments were done in a noncoculture configuration to
determine the direct effects of low-serum (0.4%) medium on both VSMC
and endothelial cell number, cell protein, and cell
viability. Results were compared with growth in medium supplemented
with 15% serum. Compared with VSMCs or endothelium
grown in normal medium, there was a significant decrease in total cell
protein and cell number. There was no significant difference in cell
viability with either VSMCs or endothelium when cells
were grown in low-serum medium (Table
). The decrease in
endothelial cell protein was accompanied by a
proportional decrease in cell number (41.6±14.98% reduction in
protein; 33.5±5.5% reduction in cell count relative to cells grown in
15% serum). The decrease in VSMC protein was accompanied by a
proportionally larger decrease in cell number (43.8±4.2% reduction in
total protein; 63±1.9% reduction in VSMC count relative to cells
grown in 15% serum). These data suggest that in low-serum medium there
is decreased cell division, with no change in cell viability or
survival.
|
Time Course for Coculture Response
The collagen I and collagen III concentrations in the growth
medium of cocultures incubated for 6, 12, 24, and 36 hours were
quantitatively determined. At 24 and 36 hours, coculture with
endothelium resulted in a significant time-dependent
increase in collagen I compared with VSMCs without
endothelium (Fig 2A
).
|
In contrast to the findings with collagen I, at 12, 24, and 36 hours,
the presence of endothelium resulted in a significant
time-dependent decrease in collagen III concentration compared with
cultures of VSMCs alone (Fig 2B
).
Effects of Endothelium Coculture on VSMC Collagen
I Concentrations
Collagen I
Under basal, coculture conditions without any
antagonists, the growth medium concentration of
VSMC-derived collagen I was significantly increased compared with that
measured in the absence of endothelium (Fig 3
, inset). After blockade of
endogenously produced NO with L-NAME (50 µmol/L) and
in the presence of indomethacin, there was a
significant augmentation of the endothelial cell
stimulatory effect on collagen I concentration compared with that
observed in cocultures of endothelium and VSMCs without
drug (Fig 3
inset compared with Fig 3
, L-NAME+indomethacin). Identical experiments were done
with N
-nitro-D-arginine
methyl ester, and the effects observed after L-NAME were not seen,
consistent with the stereoisomer-specific effect of L-NAME.
|
In cultures of VSMCs alone without endothelium, incubation with L-NAME and indomethacin resulted in a decrease in collagen I concentration; however, this result was not statistically significantly different from control VSMC cultures without endothelium (P>.05).
Collagen III
Under basal, coculture conditions without any
antagonists, the growth medium concentration of collagen
III was significantly decreased when endothelium was
present for 36 hours (Fig 4
, inset).
|
After blockade of endogenously produced NO with L-NAME and
in the presence of L-NAME, there was a reversal of the
inhibitory effect previously observed in cocultures of
endothelium and VSMCs without drug. L-NAME resulted in
a significant increase in collagen III concentration in contrast to the
decrease seen without drug (Fig 4
). However, there was no significant
difference between cocultures of endothelium and VSMCs
compared with VSMCs alone treated with L-NAME and
indomethacin.
In cultures of VSMCs alone without endothelium, incubation with L-NAME and indomethacin trended toward a further decrease in collagen III that did not reach statistical significance when compared with control cultures of VSMCs alone.
| Discussion |
|---|
|
|
|---|
The experimental design employed here depended on the presence of basal release of NO, which, via a paracrine mechanism, was hypothesized to alter VSMC collagen metabolism. We have previously measured basal release of NO, prostacyclin, and prostaglandin E2 from endothelium,27 as well as inhibition of NO production, with the concentration of L-NAME used in this study. Thus, we had prior evidence that L-NAME at the concentration used would abolish endogenous NO production. In an effort to decrease potential complications via the production of prostanoids, indomethacin was added to the coculture experiments as part of the experimental design. The increase in collagen I concentration after inhibition of NO production was observed only after cyclooxygenase inhibition, since L-NAME alone had no significant effect. This observation is consistent with complex interactions between cyclooxygenase and NOS. To uncover the effects of NO in this particular study, prostanoid production was inhibited. The exact mechanism underlying this observation is presently not known.
The mechanism(s) responsible for the net increase in collagen I or net decrease in collagen III in the coculture system elicited by the endothelium may involve complex interactions between several paracrine agents that affect both synthesis and breakdown of soluble fibrillar collagen. Since we measured collagen concentration, the data here do not distinguish between altered synthesis and/or breakdown. The alteration of endogenous NO production could result in altered breakdown of collagen I by increased or decreased production of metalloproteinases and/or decreased tissue inhibitor of metalloproteinase (TIMP) levels.
Our previous data indicated that cultured coronary VSMCs do not produce NO basally. Thus, the effects of NOS inhibition most likely reflect the effects of endothelium alone.
The observation that cocultures of endothelium and
VSMCs increase VSMC-derived collagen I concentration and decrease
VSMC-derived collagen III concentration in the growth medium concurs
with previous reports from rat fibroblasts cocultured with bovine
aortic endothelium.28 However,
the current data provided new information complementing these
observations because they (1) used endothelium and
VSMCs from the same vasculature bed (ie, coronary), (2)
implicate a mechanistic role for the endogenously derived
endothelial paracrine agent NO in extracellular matrix
metabolism, and (3) quantified the most abundant collagen
subtypes (I and III) in the vascular wall. The ability of NO to
modulate collagen metabolism has been previously reported
in noncoronary tissue. Trachtman et al29
reversed the effect of
-interferon and lipopolysaccharide on
renal mesangial cell accumulation of matrix collagens by
inhibiting NOS with L-NAME. Previous experiments have demonstrated that
NO donors added directly to the VSMC growth medium decreased collagen I
concentrations, but not collagen III
concentrations.21 Kolpakov et
al22 have also previously found that NO inhibits
total protein and collagen synthesis in noncoronary VSMCs.
Coculture conditions were strictly controlled with regard to cell number and the coculture configuration. Identical numbers of cells were seeded for any particular experiment and grown in low-serum medium sufficient to maintain viability but arrest cell division. We have found that growth in no serum results in cell death and precludes long-term incubations such as the ones we used here. However, 0.4% serum did not alter viability significantly over the time courses used. Since all cells were grown under identical conditions, the decrease in VSMC protein during coculture with endothelium is consistent with antimitogenic effects of endothelium-derived factor(s). Although the identity of the exact factor(s) is unknown, this observation is in agreement with previously published data on the antimitogenic effects of NO.21
In summary, endogenously derived endothelial cell products, via a paracrine mechanism, can alter extracellular matrix metabolism. The coronary artery endothelium cocultured with coronary VSMCs resulted in a time-dependent increase in the concentration of collagen type I, but not collagen type III; instead, collagen type III decreased. After inhibition of NO production, there was a marked increase in collagen type I and a smaller increase in collagen type III concentrations. The data support an inhibitory role for NO on collagen type I and collagen type III production and suggest that diseases impairing endogenous production of NO may adversely affect an important regulatory mechanism underlying the control of vascular collagen metabolism.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received March 11, 1997; accepted December 2, 1997.
| References |
|---|
|
|
|---|
2. Tanner F, Boulanger C, Luscher T. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Semin Thromb Hemost. 1993;19:167175.[Medline] [Order article via Infotrieve]
3. Meng Y, Trachtenburg J, Ryan U, Abendschein D. Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteries. J Am Coll Cardiol.. 1995;25:269275.[Abstract]
4. Lau Y, Ma W. Nitric oxide inhibits migration of cultured endothelial cells. Biochem Biophys Res Commun.. 1996;221:670674.[Medline] [Order article via Infotrieve]
5. Rizvi M, Myers P. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Cell Mol Cardiol.. 1997;29:17791789.
6. Sarker R, Webb R, Stanley J. Nitric oxide inhibition of endothelial cell mitogenesis and proliferation. Surgery.. 1995;118:274279.[Medline] [Order article via Infotrieve]
7. Yang W, Ando J, Korenaga R, Toyooka T, Kamiya A. Exogenous nitric oxide inhibits proliferation of cultured vascular endothelial cells. Biochem Biophys Res Commun.. 1994;203:11601167.[Medline] [Order article via Infotrieve]
8.
Sarker R, Meinberg E, Stanley J, Gordon D, Webb R.
Nitric oxide reversibly inhibits the migration of cultured vascular
smooth muscle cells. Circ Res.. 1996;78:225230.
9. Nussler A, Billiar T. Review: inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol.. 1993;54:171178.[Abstract]
10. Laskin J, Heck D, Laskin D. Multifunctional role of nitric oxide in inflammation. Trends Endocrinol Metab.. 1994;5:377382.[Medline] [Order article via Infotrieve]
11. Lyons C. The role of nitric oxide in inflammation. Adv Immunol.. 1995;60:323371.[Medline] [Order article via Infotrieve]
12. Meredith I, Yeung A, Weidinger F, Anderson T, Uehata A, Ryan T, Selwyn A, Ganz P. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation. 1993;87(suppl V):V-56-V-66.
13. Lloyd-Jones D, Bloch K. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med.. 1996;47:365375.[Medline] [Order article via Infotrieve]
14. Radomski M, Salas E. Nitric oxide: biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis. 1996;118(suppl):S69S80.
15.
Cayatte A, Palacino J, Horten K, Cohen R. Chronic
inhibition of nitric oxide production accelerates
neointima formation and impairs endothelial
function in hypercholesterolemic rabbits.
Arterioscler Thromb. 1994;14:753759.
16.
Von der Leyen H, Gibbons G, Morishita R, Lewis N, Zhang
L, Nakajima M, Kaneda Y, Cooke J, Dzau V. Gene therapy inhibiting
neointimal vascular lesion: in vivo transfer of
endothelial cell nitric oxide synthase gene. Proc
Natl Acad Sci U S A.. 1995;92:11371141.
17. Arthur J, Dusting G, Woodman O. Impaired vasodilator function of nitric oxide associated with developing neo-intima in conscious rabbits. J Vasc Res.. 1994;31:187194.[Medline] [Order article via Infotrieve]
18. Rauterberg J, Jaeger E. Collagen and collagen synthesis in the atherosclerotic vessel wall. In: Robenek H, Severs N, eds. Cell Interactions in Atherosclerosis. Boca Raton, Fla: CRC Press; 1992:101135.
19. Guarda E, Katwa L, Campbell S, Tanner M, Webel R, Laughlin H, Jenkins S, Myers P. Extracellular matrix collagen synthesis and degradation following coronary balloon angioplasty. J Mol Cell Cardiol.. 1996;28:699706.[Medline] [Order article via Infotrieve]
20. Schwartz C, Valente A, Sprague E, Hildebrandt E, Kelley J. The pathogenesis of atherosclerosis: current concepts. Am J Cardiol. 1993;71:11B17B.
21. Rizvi M, Myers P. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Cell Mol Cardiol.. 1997;29:17791789.
22.
Kolpakov V, Gordon D, Kulik T. Nitric oxidegenerating
compounds inhibit total protein and collagen synthesis in cultured
vascular smooth muscle cells. Circ Res.. 1995;76:305309.
23. Engvall E. Enzyme immunoassay ELISA and EMIT. Methods Enzymol.. 1980;70:419439.[Medline] [Order article via Infotrieve]
24. Buckley A, Hill K, Davidson J. Collagen metabolism. Methods Enzymol.. 1988;163:674694.[Medline] [Order article via Infotrieve]
25. Burke J, Balian G, Ross R, Bornstein P. Synthesis of types I and III procollagen and collagen by monkey aortic smooth muscle cells in vitro. Biochemistry. 1977;16:32433249.[Medline] [Order article via Infotrieve]
26. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248254.[Medline] [Order article via Infotrieve]
27. Xu X, Tanner M, Myers P. Prostaglandin-mediated inhibition of nitric oxide production by bovine aortic endothelium during hypoxia. Cardiovasc Res.. 1995;30:345350.[Medline] [Order article via Infotrieve]
28.
Guarda E, Myers P, Brilla C, Tyagi S, Weber K.
Endothelial cell-induced modulation of cardiac
fibroblast collagen metabolism. Cardiovasc Res.. 1993;27:10041008.
29. Trachtman H, Futterweit S, Singhal P. Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Commun.. 1995;207:120125.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
E. O'Riordan, N. Mendelev, S. Patschan, D. Patschan, J. Eskander, L. Cohen-Gould, P. Chander, and M. S. Goligorsky Chronic NOS inhibition actuates endothelial-mesenchymal transformation Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H285 - H294. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bitar, A. Lerman, M. W. Akhter, P. Hatamizadeh, M. Janmohamed, S. Khan, and U. Elkayam Variable response of conductance and resistance coronary arteries to endothelial stimulation in patients with heart failure due to nonischemic dilated cardiomyopathy. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 197 - 202. [Abstract] [PDF] |
||||
![]() |
R. M. Fitch, J. C. Rutledge, Y.-X. Wang, A. F. Powers, J.-L. Tseng, T. Clary, and G. M. Rubanyi Synergistic effect of angiotensin II and nitric oxide synthase inhibitor in increasing aortic stiffness in mice Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1190 - H1198. [Abstract] [Full Text] [PDF] |
||||
![]() |
N M Rajamannan, M Subramaniam, S R Stock, N J Stone, M Springett, K I Ignatiev, J P McConnell, R J Singh, R O Bonow, and T C Spelsberg Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve Heart, June 1, 2005; 91(6): 806 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. von der Thusen, M. L. Fekkes, R. Passier, A.J. van Zonneveld, V. Mainfroid, T. J.C. van Berkel, and E. A.L. Biessen Adenoviral Transfer of Endothelial Nitric Oxide Synthase Attenuates Lesion Formation in a Novel Murine Model of Postangioplasty Restenosis Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 357 - 362. [Abstract] [Full Text] |
||||
![]() |
J.-J. Chiu, L.-J. Chen, P.-L. Lee, C.-I Lee, L.-W. Lo, S. Usami, and S. Chien Shear stress inhibits adhesion molecule expression in vascular endothelial cells induced by coculture with smooth muscle cells Blood, April 1, 2003; 101(7): 2667 - 2674. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Yan, D. Kim, T. Aizawa, and B. C. Berk Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 26 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. I Romero, D.-N. Zhang, J. P Cooke, H.-K. V Ho, E. Avalos, R. Herrera, and G S. Herron Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma Vascular Medicine, August 1, 2000; 5(3): 147 - 158. [Abstract] [PDF] |
||||
![]() |
K. M. Channon, H. Qian, and S. E. George Nitric Oxide Synthase in Atherosclerosis and Vascular Injury : Insights From Experimental Gene Therapy Arterioscler Thromb Vasc Biol, August 1, 2000; 20(8): 1873 - 1881. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Elbaz, O. Poirier, T. Moulin, F. Chedru, F. Cambien, and P. Amarenco Association Between the Glu298Asp Polymorphism in the Endothelial Constitutive Nitric Oxide Synthase Gene and Brain Infarction Stroke, July 1, 2000; 31(7): 1634 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Jeremy, D. Rowe, A. M. Emsley, and A. C. Newby Nitric oxide and the proliferation of vascular smooth muscle cells Cardiovasc Res, August 15, 1999; 43(3): 580 - 594. [Full Text] [PDF] |
||||
![]() |
M. D. Rekhter Collagen synthesis in atherosclerosis: too much and not enough Cardiovasc Res, February 1, 1999; 41(2): 376 - 384. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |